D. E. Shaw & Co. Inc. Sells 87,556 Shares of Enovis Co. (NYSE:ENOV)

D. E. Shaw & Co. Inc. lowered its position in shares of Enovis Co. (NYSE:ENOV - Free Report) by 89.9% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 9,849 shares of the company's stock after selling 87,556 shares during the period. D. E. Shaw & Co. Inc.'s holdings in Enovis were worth $432,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in ENOV. Aster Capital Management DIFC Ltd bought a new stake in Enovis during the fourth quarter worth about $29,000. Quadrant Capital Group LLC lifted its stake in Enovis by 53.0% during the fourth quarter. Quadrant Capital Group LLC now owns 690 shares of the company's stock worth $30,000 after purchasing an additional 239 shares during the last quarter. Quarry LP increased its holdings in shares of Enovis by 506.1% in the fourth quarter. Quarry LP now owns 897 shares of the company's stock worth $39,000 after buying an additional 749 shares during the period. Sterling Capital Management LLC increased its holdings in shares of Enovis by 56.2% in the fourth quarter. Sterling Capital Management LLC now owns 3,259 shares of the company's stock worth $143,000 after buying an additional 1,173 shares during the period. Finally, Legacy Capital Wealth Partners LLC purchased a new position in shares of Enovis in the fourth quarter worth about $228,000. Institutional investors own 98.45% of the company's stock.

Enovis Trading Down 1.2%

NYSE:ENOV traded down $0.39 during mid-day trading on Friday, reaching $31.66. 412,312 shares of the company's stock traded hands, compared to its average volume of 793,010. Enovis Co. has a 12-month low of $29.32 and a 12-month high of $51.00. The firm has a market capitalization of $1.81 billion, a price-to-earnings ratio of -14.42 and a beta of 1.79. The company has a debt-to-equity ratio of 0.40, a current ratio of 2.27 and a quick ratio of 1.12. The company has a 50 day moving average price of $34.16 and a 200-day moving average price of $40.70.

Enovis (NYSE:ENOV - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The company reported $0.81 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.74 by $0.07. The company had revenue of $558.83 million for the quarter, compared to the consensus estimate of $558.80 million. Enovis had a positive return on equity of 4.39% and a negative net margin of 5.95%. Enovis's revenue was up 8.2% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.50 EPS. On average, sell-side analysts predict that Enovis Co. will post 2.79 earnings per share for the current year.

Analyst Upgrades and Downgrades

ENOV has been the topic of several analyst reports. JMP Securities decreased their price objective on Enovis from $62.00 to $55.00 and set a "market outperform" rating on the stock in a report on Friday, May 9th. Canaccord Genuity Group decreased their price objective on Enovis from $75.00 to $70.00 and set a "buy" rating on the stock in a report on Wednesday, May 14th. Finally, Needham & Company LLC decreased their price objective on Enovis from $64.00 to $57.00 and set a "buy" rating on the stock in a report on Friday, May 9th. One analyst has rated the stock with a hold rating and four have given a buy rating to the company's stock. Based on data from MarketBeat.com, Enovis currently has a consensus rating of "Moderate Buy" and an average price target of $58.00.

Enovis Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.